Start with its own history
Compare positive annual observations to understand how this company has been priced over time. A lower multiple can reflect a lower price, higher earnings, or weaker growth expectations—not necessarily a bargain.
SHH · 688837.SSBiotechnologyUpdated Oct 23, 2026
Evopoint Biosciences Co. Ltd. P/E ratio
Current valuation, historical context, and peer comparisons.
Current P/E ratio
41.78×
Historical comparison unavailable.
Share price39.19
÷Earnings per share0.938
Price and EPS in quote currency. Calculation details
Investors are paying 41.78 for every 1 of reported earnings per share.
P/E over time
Not enough positive observations to chart this period. Available values are listed below.
Annual P/ESelected-period average N/M
3-year averageN/M0 positive annual observations
5-year averageN/M0 positive annual observations
10-year averageN/M0 positive annual observations
Peer median · TTM23.87×6 peers with positive P/E
Historical P/E ratios
Annual period-end data · 0 observations
Annual history is not available yet.
Change is relative to the preceding observation. N/M values are excluded from averages.
How 688837.SS compares
Company P/E vs. peer trailing-12-month ratios
| Company | P/E ratio |
|---|---|
 688837.SS This stockEvopoint Biosciences Co. Ltd. | 41.78× |
 688321.SSShenzhen Chipscreen Biosciences Co., Ltd. | 105.00× |
 688331.SSRemeGen Co. Ltd. Class A | 9.74× |
 688578.SSShanghai Allist Pharmaceuticals Co., Ltd. | 14.86× |
 688176.SSJiangsu Yahong Meditech Co Ltd | N/M |
 300558.SZBetta Pharmaceuticals Co., Ltd. | 38.32× |
 688513.SSChengdu Easton Biopharmaceuticals Co., Ltd. | 28.93× |
 688136.SSKexing Biopharm Co., Ltd. | 18.81× |
 300204.SZStaidson (Beijing) BioPharmaceuticals Co., Ltd. | N/M |
Peers are selected by the data provider. Business models and earnings definitions can differ.
Put the numbers in context
What does 688837.SS’s P/E tell you?
Compare like with like
The median of the 6 positive peer ratios above is 23.87×. Check growth, margins, debt, and earnings quality before interpreting the gap. A faster-growing business may justify a higher multiple.
Check what drives earnings
One-off gains can temporarily lower P/E; unusual charges can raise it. Reported earnings and forward estimates answer different questions. Pair this view with return on equity and liquidity for a fuller picture.
Keep your research connected
Take 688837.SS into your spreadsheet
Pull historical P/E into Excel or Google Sheets with Wisesheets. Build your own comparisons alongside the rest of your financial model.
Explore WisesheetsQuarterly P/E · latest quarterLQ selects the latest reported quarter. Requires the Wisesheets add-in. See available data
=WISE("688837.SS", "PE Ratio", "LQ")Sources & calculation methodology
Current P/E
Share price 39.19 ÷ EPS 0.938 = 41.78×. Data is supplied by Financial Modeling Prep through Wisesheets. Quote feed updated Oct 23, 2026; this is not a real-time trading quote.
History & averages
Annual and quarterly P/E observations are provided separately from the current quote. Averages use the latest 3, 5, or 10 annual observations, excluding missing and nonpositive ratios. Pre-IPO observations are omitted. These are period-end observations, not daily averages.
Data definitions and limitations
The current quote feed does not specify the exact EPS filing-period end or whether EPS is basic or diluted. We do not label it as forward P/E. Peer ratios are explicitly trailing-12-month (TTM) values. Historical observations do not include independently verified price and EPS inputs. Sources may update on different schedules; rounded inputs can produce small calculation differences. Historical comparisons describe past pricing, not an estimate of fair value.
688837.SS P/E ratio: common questions
The essentials behind the numbers.
Evopoint Biosciences Co. Ltd.'s current P/E is 41.78× based on the quote data last updated Oct 23, 2026. It represents the share price divided by reported earnings per share. Prices and earnings may refresh on different schedules.
Annual P/E uses earnings for a completed fiscal year. Trailing-12-month (TTM) P/E uses the latest four quarters, while forward P/E uses forecast earnings. These are not interchangeable. This page labels peer ratios as TTM and shows dated annual or quarterly historical observations; it does not show forward estimates.
N/M means not meaningful: the feed has no positive P/E for that observation. Negative or zero earnings should not be ranked as a low positive valuation multiple. N/M observations are excluded from the averages shown above.
Divide the share price by earnings per share (EPS). For example, a share price of 100 and EPS of 5 gives a P/E of 20×. This page uses the price and EPS supplied together in the quote when both are positive.
Price timestamps, EPS definitions, share classes, adjustments, and fiscal periods can differ. A forward P/E also uses forecast earnings rather than reported earnings. Compare the inputs and as-of dates before comparing two displayed ratios.
Not necessarily. The average describes previous market pricing, not fair value. Changes in earnings quality, growth expectations, debt, accounting, and business risk can justify a different multiple today.